Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...
Introduction Maximising the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results